Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL535175 | 0.81 | ALDH1A1 (0.40) | ALDH1A1RXFP1ATMKDM4EPOLB | |
| SCHEMBL535667 | 0.76 | KDM4E (0.35) | ALDH1A1KDM4EPOLBHSD17B10PTGS2 | |
| SCHEMBL27654704 | 0.72 | ALDH1A1 (0.42) | ALDH1A1KDM4EPOLBLMNA | |
| SCHEMBL13310099 | 0.72 | ALDH1A1 (0.41) | ALDH1A1ATMKDM4ELMNAMAPT | |
| SCHEMBL14282484 | 0.68 | ALDH1A1 (0.47) | ALDH1A1PTGDR2KDM4EPOLBLMNA | |
| SCHEMBL4772659 | 0.65 | ALDH1A1 (0.47) | ALDH1A1KDM4EPOLBLMNAGLA | |
| SCHEMBL10035025 | 0.65 | ALDH1A1 (0.39) | ALDH1A1RXFP1PTGS2LMNAMAPT | |
| SCHEMBL6432623 | 0.65 | ALDH1A1 (0.54) | ALDH1A1LMNAMAPTSMN1; SMN2APOBEC3A | |
| SCHEMBL21642625 | 0.65 | ALDH1A1 (0.54) | ALDH1A1LMNAMAPTSMN1; SMN2APOBEC3A | |
| SCHEMBL21642626 | 0.65 | ALDH1A1 (0.54) | ALDH1A1LMNAMAPTSMN1; SMN2APOBEC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160207938-A1 | QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-21 | — | — | US | disclosed |
| US-9365517-B2 | 3-cyano-quinoline derivatives with antiproliferative activity | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-14 | — | — | US | disclosed |
| US-9273013-B2 | Quinazoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-01 | — | — | US | disclosed |
| US-9040511-B2 | 3-cyano-quinoline derivatives with antiproliferative activity | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-26 | — | — | US | disclosed |
| US-20140256948-A1 | 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | disclosed |
| US-8778920-B2 | 3-cyano-quinoline derivatives with antiproliferative activity | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-15 | — | — | US | disclosed |
| US-20130197022-A1 | 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-08-01 | — | — | US | disclosed |
| US-20130178624-A1 | QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-11 | — | — | US | disclosed |
| US-8394786-B2 | Quinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| EP-1633365-B1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-08 | — | — | EP | disclosed |
| EP-2305687-A1 | Quinazoline derivatives | Janssen Pharmaceutica NV (BE) | 2011-04-06 | — | — | EP | disclosed |
| US-20100105668-A1 | Quinazoline derivatives | FREYNE EDDY JEAN EDGARD | 2010-04-29 | — | — | US | disclosed |
| US-20100069424-A1 | 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY | FREYNE EDDY JEAN EDGARD | 2010-03-18 | — | — | US | disclosed |
| EP-1696914-B1 | 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-28 | — | — | EP | disclosed |
| EP-1633365-A1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004105765-A1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178624-A1 | QUINAZOLINE DERIVATIVES | NR1H2, NR1H3, NR3C2 | ALDH1A1 2807/4885RXFP1 951/4885ATM 3993/4885 |
| US-20140256948-A1 | 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY | NR1H3, NR1H2, NR1D1 | ALDH1A1 2452/4885RXFP1 1228/4885ATM 4656/4885 |
| US-20130197022-A1 | 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY | NR1H3, NR1H2, NR1D1 | ALDH1A1 2452/4885RXFP1 1228/4885ATM 4656/4885 |
| US-20100105668-A1 | Quinazoline derivatives | NR1H2, NR1H3, NR3C2 | ALDH1A1 2784/4885RXFP1 913/4885ATM 3959/4885 |
| US-20100069424-A1 | 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY | NR1H3, NR1H2, NR1D1 | ALDH1A1 2452/4885RXFP1 1228/4885ATM 4656/4885 |
| US-20160207938-A1 | QUINAZOLINE DERIVATIVES | NR1H2, NR1H3, NR3C2 | ALDH1A1 2932/4885RXFP1 696/4885ATM 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.